Global Financial Private Client’s BioMarin Pharmaceuticals BMRN Stock Holding History

Global Financial Private Client’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-28	Closed	-$1.98K	–	391
2025 Q1	$1.98K	Buy	28 +16	+133%	+$1.08K	﹤0.01%	867
2024 Q4	$789	Buy	12 +5	+71%	+$335	﹤0.01%	829
2024 Q3	$492	Hold	7	–	–	﹤0.01%	784
2024 Q2	$576	Hold	7	–	–	﹤0.01%	649
2024 Q1	$610	Hold	7	–	–	﹤0.01%	662
2023 Q4	$675	Hold	7	–	–	﹤0.01%	649
2023 Q3	$610	Hold	7	–	–	﹤0.01%	634
2023 Q2	$601	Hold	7	–	–	﹤0.01%	639
2023 Q1	$676	Hold	7	–	–	﹤0.01%	637
2022 Q4	$724	Hold	7	–	–	﹤0.01%	624
2022 Q3	$607	Hold	7	–	–	﹤0.01%	606
2022 Q2	$595	Hold	7	–	–	﹤0.01%	601
2022 Q1	$555	Hold	7	–	–	﹤0.01%	622
2021 Q4	$618	Hold	7	–	–	﹤0.01%	610
2021 Q3	$540	Hold	7	–	–	﹤0.01%	572
2021 Q2	$587	Hold	7	–	–	﹤0.01%	571
2021 Q1	$545	Hold	7	–	–	﹤0.01%	548
2020 Q4	$614	Buy	+7	New	+$555	﹤0.01%	522

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Global Financial Private Client's BMRN Position: Q2 2025 in Review

Global Financial Private Client sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 28 shares — an estimated $1.98K sold.

Global Financial Private Client first reported a position in BMRN in Q4 2020 and held it in 18 quarters. The position peaked at $1.98K in Q1 2025. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Global Financial Private Client reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Global Financial Private Client sold 28 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $1.98K.
Global Financial Private Client first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 18 quarters.
Global Financial Private Client's BioMarin Pharmaceuticals position peaked at $1.98K in Q1 2025.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.